Nymox Reports on Symposium and Panel Discussion on NX-1207 at American Urological Association Annual Meeting

Pivotal Phase 3 Trials for NX-1207 for BPH Have Now Completed Enrollment

        Print
| Source: Nymox Pharmaceutical Corporation

HASBROUCK HEIGHTS, N.J., May 6, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the presentation on NX-1207 drug studies at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Diego, CA between 3:00 and 4:00 pm PDT on Sunday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH) and featured expert panel discussions on the new therapy. The Company is pleased to report that the pivotal U.S. Phase 3 trials of NX-1207 for BPH, NX02-0017 and NX02-0018, have now completed enrollment.

The symposium, "Clinical studies of NX-1207: Phase 3 Injectable for BPH (Phase 2 for Prostate Cancer)," was chaired by Ronald F. Tutrone Jr., MD, FACS of Towson, MD. The other panel members at the Symposium were Dr. Mohamed Bidair of San Diego CA, Dr. Susan J. Kalota of Tucson AZ, Dr. Franklin D. Gaylis of San Diego CA, Dr. Sheldon Freedman of Las Vegas NV, Dr. Eugene Dula of Tarzana CA, and Dr. Michael T. Gambla of Columbus OH.

According to Dr. Tutrone, "I will be excited to see the results from the Phase 3 trials. I feel that NX-1207 has the potential to be a game changer in BPH and to dramatically improve the quality of life for men that suffer from BPH."

Dr. Dula said that NX-1207 is "the most innocuous and quick therapy for BPH. It delivers the medicine where you need it."

Dr. Kalota said that in her experience "NX-1207 is easy to inject and well tolerated and frequently produces excellent results."

Dr. Bidair said that NX-1207 was "extremely well tolerated."  He added that it took "less time to perform the procedure than to get the patient ready on the table."

Dr. Gaylis was of the opinion that NX-1207 was "an attractive novel therapy for BPH and for local low risk prostate cancer."

Dr. Freedman said "I think that NX-1207 is an out-of-the-box treatment like nothing else. There has never been an easier treatment for this affliction."

Dr. Gambla said that NX-1207 "is the least minimally invasive therapy I am aware of."

The first pivotal Phase 3 U.S. study of NX-1207 for BPH (NX02-0017) completed enrollment in November 2012; the second (NX02-0018) in April 2013. Overall, NX-1207 is being evaluated in six large studies, including two safety reinjection studies (NX02-0020 and NX02-0022), a European pivotal study (ERNEST) being conducted by Recordati S.p.A, the Company's European partner, and a U.S. Phase 2 prostate cancer study (NX03-0040). The Company previously successfully completed four Phase 1 and Phase 2 clinical trials of NX-1207 for BPH as well as over ten additional follow-up studies.

The Symposium presented further scientific data on the results of immunological testing of patients who received NX-1207. Current data shows no evidence of antibody formation against NX-1207 or hypersensitivity to NX-1207 in men. In addition, updated pharmacokinetic studies have provided further evidence to corroborate the absence of systemic toxicities for NX-1207. To date, the safety profile of NX-1207 has been excellent.

NX-1207 is a novel patented drug developed by Nymox which is currently in late stage Phase 3 trials for benign prostatic hyperplasia (BPH) and Phase 2 for localized prostate cancer. NX-1207 is injected into the sector of prostate to be treated by a urologist in a clinic setting. The procedure does not require catheterization, anesthesia, or sedation, takes only a few minutes and involves little or no pain or discomfort to the patient. In multi-center U.S. clinical trials for BPH to date, a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting improvement in BPH symptoms without other treatments for up to 7½ years.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com